ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2008
siRNA silencing of angiotensin-converting enzyme 2 reduced severe acute respiratory syndrome-associated coronavirus replications in Vero E6 cells.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- SARS-CoV-2 Syncytium under the Radar: Molecular Insights of the Spike-Induced Syncytia and Potential Strategies to Limit SARS-CoV-2 Replication.Journal of clinical medicine · 2023Review
- Antisense technology as a potential strategy for the treatment of coronaviruses infection: With focus on COVID-19.IET nanobiotechnology · 2022Review
- Roles of steroid receptors in the lung and COVID-19.Essays in biochemistry · 2021Review
- Gene editing and RNAi approaches for COVID-19 diagnostics and therapeutics.Gene therapy · 2021Review
- Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2.Scientific reports · 2021Article
- Nucleic Acid-Based Technologies Targeting Coronaviruses.Trends in biochemical sciences · 2021Review
- Review
- Relationship Between COVID-19 and Angiotensin-Converting Enzyme 2: A Scoping Review.Advances in experimental medicine and biology · 2021Article
- The Potential Therapeutic Effect of RNA Interference and Natural Products on COVID-19: A Review of the Coronaviruses Infection.Frontiers in pharmacology · 2021Review
- Nucleic Acid-Based Treatments Against COVID-19: Potential Efficacy of Aptamers and siRNAs.Frontiers in microbiology · 2021Review
- Non-Coding RNAs and SARS-Related Coronaviruses.Viruses · 2020Review
- SARS-CoV-2 and the possible connection to ERs, ACE2, and RAGE: Focus on susceptibility factors.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020Review
- Coronavirus pandemic: treatment and future prevention.Future microbiology · 2020Article
- Lessons from SARS and MERS remind us of the possible therapeutic effects of implementing a siRNA strategy to target COVID-19: Shoot the messenger!Journal of cellular and molecular medicine · 2020Article
- Viral Vectors Applied for RNAi-Based Antiviral Therapy.Viruses · 2020Review
- Coronavirus Pandemic-Therapy and Vaccines.Biomedicines · 2020Review
- Upregulation of the chemokine (C-C motif) ligand 2 via a severe acute respiratory syndrome coronavirus spike-ACE2 signaling pathway.Journal of virology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The outbreak of severe acute respiratory syndrome (SARS) in 2002-2003 has had a significant impact worldwide. No effective prophylaxis or treatment for SARS is available up to now. Angiotensin-converting enzyme 2 (ACE2) is the cellular receptor for SARS-associated coronavirus (SARS-CoV). By expressing a U6 promoter-driven small interfering RNA containing sequences homologous to part of ACE2 mRNA, we successfully silenced ACE2 expression in Vero E6 cells. By detecting negative strand SARS-CoV RNA and measuring RNA copy numbers of SARS-CoV by real-time reverse transcription polymerase chain reaction (RT-PCR), we demonstrated that SARS-CoV infection was reduced in the ACE2-silenced cell lines. These findings support the involvement of ACE2 in SARS-CoV infections and provide a basis for further studies on potential use of siRNA targeting ACE2 as a preventive or therapeutic strategy for SARS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.